Associate Director – Hemophilia Gene Therapy Global Marketing
Location :San Rafael, California
Workstyle :Open to Hybrid
With accelerated review underway in the United States and Europe for our Hemophilia A drug, a second gene therapy program entering the clinic for PKU patients, and a third program in late research for Hereditary Angioedema, BioMarin continues to pioneer innovative approaches to treating rare diseases. Our commitment to gene therapy is further underscored by having developed the first and largest gene therapy manufacturing facility in the world. The scientific possibilities and the hope we offer to patients with rare diseases is enormous.
BioMarin is a midsize biotechnology company with a market cap of approximately 18 billion. Over the course of our 22 year history we have successfully launched 7 drugs for the treatment of rare diseases. Our success is due to our scientific rigor and our ability to leverage multiple therapeutic modalities. BioMarin is based in the San Francisco Bay Area and offers a comprehensive relocation program.
Check out the traits we’re looking for and see if you have the right mix.
- Decision Making
- Intellectual Curiosity
- Patient Focused
- Results Oriented
- Pioneering Science
- Cross Functional Collaboration
- Willing to try new ways to look at problems
Health & Wellness Programs
" BioMarin has this, in their own DNA, an approach: they only work on projects for which they know the underlying biology."Lon C., Chief Scientific Officer
"We’ve got to understand: What are the problems other people are trying to solve? And do we have a better way of fundamentally doing that?"Brinda B, GVP, Corporate and Business Development
BioMarin is the world leader in delivering therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. We target diseases that lack effective therapies and affect relatively small numbers of patients, many of whom are children. These conditions are often inherited, difficult to diagnose, progressively debilitating and have few, if any, treatment options. BioMarin will continue to focus on advancing therapies that are the first or best of their kind.
BioMarin’s Commercial organization supports our global sales and marketing efforts around the world. Our global sales force continues to solidify the company’s commercial presence in the United States and Europe and is rapidly growing in other regions, such as Latin America, the Middle East and Asia-Pacific. Come join our team and make a meaningful impact on patients’ lives.
This key role on the Global Commercial [ROCTAVIAN or valoctacogene roxoparvovex] Team is focused on driving pre and post-launch commercialization efforts for our innovative and life-changing hemophilia A gene therapy, currently under review in Europe, and soon to be filed in the US. The position spans many areas including commercial strategy, market development, commercial planning, market insights and tactical execution. The ideal candidate will already have hemophilia experience, including a strong understanding of and respect for the empowered patient community, patient advocates and dedicated health care providers. This individual will identify critical business issues and opportunities for growth, collaborate with commercial and cross-functional teams, and develop and drive strategies to prepare for the successful launch and uptake of valoctacogene roxoparvovex.
Collaboratively engage with global community stakeholders including healthcare professionals, patient advocacy groups and patients to ensure integration of their perspectives into all plans
Develop global commercial strategies and tactics to support valoctacogene roxoparvovex.
Lead market development and pre/post-launch projects including brand development, annual brand planning, conference management and other key projects as assigned
Liaise with regional commercial, medical affairs and other cross functional colleagues to gain alignment on objectives, advance projects from inception to completion, and ensure pull-through.
External agency management of key deliverables and budgets.
We are searching for a passionate individual with a genuine commitment to advancing hemophilia care. The candidate will have 10+ years of pharmaceutical/biotech marketing experience and ideally 2+ years of hemophilia product management experience.
We need to see a demonstrated ability to think and communicate strategically, with experience facilitating cross-functional project teams, influencing internal and external stakeholders, and making tough trade-off decisions, all while ensuring strong stakeholder alignment.
Additional qualities and skills include:
Strong analytical, problem solving and contingency planning skills
Proactive and agile. Able to work independently and as part of a high-functioning, cross-functional team
Experience managing project budgets and timelines
Proficiency with PowerPoint, Excel and Word
Confident and influential presenter, adept at engaging senior leadership
Ability and willingness to travel domestically and internationally, +/- 25%+ time
Hemophilia pre-launch preparation and successful launch experience.
Experience marketing new technologies/MoAs and/or novel therapies.
History of meaningful collaborations with patient advocacy groups and health care professionals.
International/global marketing experience; keen understanding of global markets.
Experience managing agencies including advertising, digital, and market research.
Bachelor's Degree, preferably in life sciences, business or economics
MBA or other advanced degree preferred
We are an equal opportunity employer and all qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, disability status, protected veteran status, or any other characteristic protected by law.
About our location
Meet Our Team
From internationally renowned scientists to patient advocates, BioMarin Hemophilia has brought together the right people.Read More
In the News
BioMarin has entered into a preclinical collaboration and license agreement with DiNAQOR, a gene therapy platform company, to develop novel gene therapies to treat rare genetic cardiomyopathies.Learn More